BIA-ALCL
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare lymphoma associated with breast implants. Not all implants carry the same risk. This article summarizes current evidence on which implants have been associated with BIA-ALCL, what recalls have occurred, and current screening recommendations.
What is BIA-ALCL?
BIA-ALCL is a type of T-cell lymphoma that develops in the scar tissue capsule around breast implants. It is not breast cancer; it is a separate disease. Most cases:
- Present 7-10 years after implant placement
- Are confined to the capsule (early stage)
- Cured with complete capsulectomy alone when caught early
- Advanced cases require chemotherapy
Risk by implant type
The strongest association is with textured implants. Specifically:
| Implant Type | BIA-ALCL Association |
|---|---|
| Smooth surface | Very rare (some cases reported but mechanism unclear) |
| Microtextured (Mentor Siltex, etc.) | Lower risk than macrotextured |
| Macrotextured (Allergan Biocell, etc.) | Highest associated risk |
| Polyurethane-coated | Cases reported |
Manufacturer recall history
Major recall and removal events:
- Allergan Biocell — voluntary worldwide recall July 2019. Affected: Natrelle textured saline and silicone implants and tissue expanders.
- Other manufacturers have removed specific textured products from various markets over subsequent years.
- Some textured products remain available in certain markets under continued monitoring.
If you have textured implants placed before 2019, request the original surgical records to identify the specific brand and product.
How BIA-ALCL is detected
Most cases present as delayed seroma — fluid collection around the implant 7+ years after placement, often with no other symptoms.
Diagnostic workup:
- Ultrasound or MRI to confirm fluid collection
- Fluid aspiration with cytology
- Immunohistochemistry: CD30 positive, ALK negative confirms BIA-ALCL
- Capsule biopsy if mass present
- Staging studies (PET-CT) if confirmed
Screening recommendations
Current consensus for textured implant patients:
- Symptomatic patient (new swelling, pain, mass) → immediate ultrasound + workup
- Asymptomatic patient → annual breast self-examination + ultrasound every 2-3 years
- Patient considering explant → en-bloc capsulectomy + capsule pathology
Should you have textured implants removed?
This is an individual decision based on:
- Time since placement (longer = somewhat higher cumulative exposure)
- Specific implant brand and texture grade
- Patient anxiety and quality of life
- Surgical risk of explant for the individual
- Other concerns (BII, rupture, aging)
Current FDA and ASPS guidance does not mandate removal of asymptomatic textured implants. Many patients choose explant for peace of mind. Both approaches are reasonable.
Treatment outcomes
For early-stage BIA-ALCL confined to the capsule:
- Complete capsulectomy alone is curative in approximately 90% of early cases
- 5-year survival is excellent when caught early
- No chemotherapy typically needed for early stage
This is why capsule pathology after explant matters — it can detect BIA-ALCL at the earliest, most curable stage even when no symptoms were present.
Frequently Asked Questions
If I have textured implants, what should I do?
Don't panic. Schedule a consultation with a plastic surgeon experienced in BIA-ALCL. Discuss your specific implant, your risk tolerance, and your options.
Are smooth implants completely safe from BIA-ALCL?
The risk is much lower, possibly negligible, but extremely rare cases in smooth-only patients have been reported. The association with smooth implants is unclear.
How rare is BIA-ALCL really?
Estimated incidence ranges from approximately 1 in 3,000 to 1 in 30,000 patients with textured implants, depending on the implant type and population studied. It is rare but not exceptionally rare for high-risk textured products.
Have questions?
For specific questions about topics covered in this article, reach Dr. Erdal directly via WhatsApp.
Ask on WhatsApp